Alto Neuroscience (NYSE:ANRO) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a sell rating to a hold rating in a research note released on Saturday morning.

Other equities research analysts have also recently issued reports about the company. Wedbush lifted their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. HC Wainwright increased their target price on Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Robert W. Baird dropped their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Finally, BTIG Research boosted their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $35.13 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The firm has a market cap of $1.38 billion, a P/E ratio of -14.52 and a beta of 1.06. The firm’s 50 day moving average price is $28.78 and its 200-day moving average price is $24.12. Alto Neuroscience has a one year low of $3.41 and a one year high of $37.48.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. As a group, equities research analysts predict that Alto Neuroscience will post -2.68 EPS for the current year.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently modified their holdings of the stock. GK Wealth Management LLC acquired a new position in Alto Neuroscience during the 2nd quarter worth $226,000. California State Teachers Retirement System acquired a new stake in Alto Neuroscience in the 2nd quarter valued at about $251,000. Balyasny Asset Management L.P. purchased a new position in shares of Alto Neuroscience in the 4th quarter valued at about $198,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Alto Neuroscience in the 4th quarter valued at about $221,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Alto Neuroscience during the fourth quarter worth about $304,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.